RVNC - Revance Therapeutics EPS beats by $0.05 misses on revenue November, 09 2021 04:11 PM Revance Therapeutics Inc. Revance Therapeutics (NASDAQ:RVNC): Q3 GAAP EPS of -$1.10 beats by $0.05. Revenue of $19.7M (+418.4% Y/Y) misses by $0.17M. Press Release For further details see: Revance Therapeutics EPS beats by $0.05, misses on revenue